From Discovery to Preclinical Validation: Development of a Novel BRD4 Degrader via a Versatile TPD Platform
Download the Full Event Guide for Full Session Details.
- Leveraging a versatile TPD platform to rapidly discover potent degraders targeting BRD4
- Lead optimization to achieve durable anti-tumor efficacy in diverse cancer models and patientderived cells
- Presenting preclinical pharmacology insights to support clinical development